CA
NZ
UK
AU
IND
US
…
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public filings and company disclosures provide limited information on Lite Strategy, Inc.'s operating business, so its core activities are not well described in public sources. Because detailed strategy and revenue drivers are not disclosed, major long-term growth drivers are unclear; investors may find the company attractive for potential upside if management announces clear operations or strategic transactions and for Nasdaq liquidity.
Key investment risks are limited public disclosure and an unclear operating history, potential need for additional financing and dilution, low institutional coverage and small-cap liquidity and execution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
| Net income | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
| Selling general administrative | 13.53M | 23.30M | 33.13M | 30.54M | 24.41M |
| Gross profit | -0.37M | 65.30M | 48.82M | 40.70M | 33.39M |
| Reconciled depreciation | 0.37M | 0.38M | 0.39M | 0.33M | 0.28M |
| Ebit | -17.45M | 25.44M | -36.76M | -75.48M | -41.31M |
| Ebitda | -17.09M | 25.82M | -36.38M | -75.16M | -41.02M |
| Depreciation and amortization | 0.37M | 0.38M | 0.39M | 0.33M | 0.28M |
| Operating income | -17.45M | 14.54M | -36.76M | -75.48M | -60.42M |
| Other operating expenses | 17.45M | 50.76M | 85.58M | 116.18M | 95.22M |
| Tax provision | - | - | - | 0.00M | 0.01M |
| Interest income | 1.03M | 3.28M | 3.35M | 0.28M | 0.51M |
| Net interest income | 1.03M | 3.28M | 3.35M | 0.28M | 0.51M |
| Income tax expense | - | - | - | - | 0.01M |
| Total revenue | 0.00M | 65.30M | 48.82M | 40.70M | 34.80M |
| Total operating expenses | 17.09M | 50.76M | 85.58M | 116.18M | 93.81M |
| Cost of revenue | 0.37M | 0.38M | 1.81M | 1.24M | 1.41M |
| Total other income expense net | 1.51M | 3.24M | 4.93M | 21.03M | 19.12M |
| Net income from continuing ops | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 18.29M | 41.38M | 120.81M | 177.84M | 174.10M |
| Other current assets | 0.27M | 2.42M | 6.75M | 3.83M | 3.81M |
| Total liab | 1.35M | 8.36M | 96.19M | 125.43M | 124.63M |
| Total stockholder equity | 16.93M | 33.02M | 24.62M | 52.41M | 49.47M |
| Other current liab | 1.18M | 5.19M | 12.46M | 10.82M | 8.40M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -404.16M | -388.22M | -406.00M | -374.16M | -319.70M |
| Cash | 18.01M | 3.71M | 16.91M | 15.74M | 8.54M |
| Total current liabilities | 1.35M | 8.36M | 20.34M | 24.44M | 20.21M |
| Current deferred revenue | - | - | 0.32M | 4.83M | 4.53M |
| Net debt | -18.01M | -3.71M | -4.18M | -6.10M | -0.24M |
| Short term debt | - | - | 1.43M | 0.87M | 0.93M |
| Short long term debt total | - | - | 12.73M | 9.64M | 8.30M |
| Other stockholder equity | 421.10M | 421.24M | 430.62M | 426.57M | 369.17M |
| Total current assets | 18.29M | 40.77M | 107.53M | 167.13M | 164.82M |
| Short term investments | 0.00M | 34.64M | 83.79M | 137.51M | 144.88M |
| Net receivables | - | - | 0.09M | 10.04M | 7.58M |
| Accounts payable | 0.18M | 3.17M | 6.13M | 7.92M | 6.36M |
| Non current assets total | 0.00M | 0.61M | 13.28M | 10.71M | 9.28M |
| Capital lease obligations | - | 0.00M | 12.73M | 9.64M | 8.30M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | 35.15M | 49.14M | 53.69M | 6.89M | 24.71M |
| Total cashflows from investing activities | 35.15M | 49.14M | 53.69M | 6.89M | 24.71M |
| Total cash from financing activities | 0.00M | -11.87M | -0.04M | 49.05M | 3.47M |
| Net income | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
| Change in cash | 14.31M | -13.20M | 1.17M | 7.20M | -3.79M |
| Begin period cash flow | 3.71M | 16.91M | 15.74M | 8.54M | 12.33M |
| End period cash flow | 18.01M | 3.71M | 16.91M | 15.74M | 8.54M |
| Total cash from operating activities | -20.84M | -50.47M | -52.48M | -48.75M | -31.96M |
| Issuance of capital stock | - | - | 0.00M | 52.33M | 3.20M |
| Depreciation | 0.37M | 0.38M | 0.39M | 0.33M | 0.28M |
| Other cashflows from investing activities | 0.01M | - | - | - | - |
| Dividends paid | 0.00M | 11.66M | 0.00M | - | - |
| Change to account receivables | - | 0.09M | 9.96M | -2.46M | 15.70M |
| Other cashflows from financing activities | - | -0.21M | -0.04M | -3.27M | - |
| Capital expenditures | 0.00M | 0.01M | 0.04M | 0.48M | 0.71M |
| Change in working capital | -4.85M | -84.28M | -24.95M | 16.88M | 16.94M |
| Stock based compensation | -0.14M | 2.28M | 3.59M | 8.35M | 10.24M |
| Other non cash items | -0.27M | 13.36M | 0.33M | -19.84M | -7.88M |
| Free cash flow | -20.84M | -50.48M | -52.52M | -49.23M | -32.67M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LITS Lite Strategy, Inc. |
-0.06 6.25% |
0.92 | - | 4.62 | 0.31 | 0.69 | 0.81 | 2.38 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
9920 Pacific Heights Blvd., San Diego, CA, United States, 92121
858 369 7100
4
| Name | Title | Year Born |
|---|---|---|
| Mr. Justin J. File CPA | CEO, CFO, Corporate Secretary & Director | 1970 |
| Ms. Anne Frese | Chief People Officer | NA |
| Dr. Robert D. Mass M.D. | Strategic Advisor | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...